As climate change warms the planet, high ambient temperatures are expected to be more common and intense over the coming decades in the U.S. and worldwide.
Jul 4, 2024
0
64
Researchers show for the first time that engineered human plasma B cells can be used to treat a disease—specifically leukemia—in a humanized animal model. The results mark a key step in the realization of ePCs as therapies ...
Jul 2, 2024
0
52
Researchers from the University of Missouri School of Medicine found that a targeted gene therapy may make acute myeloid leukemia (AML) more sensitive to chemotherapy, while also protecting the heart against toxicity often ...
Jun 27, 2024
0
23
Understanding the molecular characteristics of cancer that impact patient outcomes is essential to identifying novel treatment strategies for the most intractable pediatric malignancies. Many of these diseases are difficult ...
Jun 26, 2024
0
0
For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields comparable relapse incidence (RI) ...
Jun 24, 2024
0
0
First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a study published online May 13 in Clinical Lymphoma, Myeloma & Leukemia.
Jun 21, 2024
0
2
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with those who didn't, according ...
Jun 21, 2024
0
0
While most cell types experience a functional decline after years of proliferation and replication, T cells can proliferate seemingly indefinitely and without detriment.
Jun 12, 2024
0
56
Valrubicin, a lipophilic chemical molecule similar to daunorubicin, has primarily been used in the treatment of bladder cancer. An article recently published in Cell Death & Disease describes the repurposing of this molecule ...
Jun 6, 2024
0
0
A new research perspective titled "Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification" has been published in Oncotarget.
Jun 4, 2024
0
0
